In summary, our study points out that catalpol is able to inhibit pulmonary fibrosis, and the mechanism may lie in down-regulating Ang II and AT1 as well as inhibiting EMT progression through the TGF-β/Smad2/3 signaling pathway. This evidence concerns the gene SMAD2 and pulmonary fibrosis.